PCM
APGE icon

Prelude Capital Management’s Apogee Therapeutics APGE Stock Holding History

Prelude Capital Management’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$505K Buy
+6,000
New +$436K 0.04% 505
2025
Q4 		– Sell
-26,241
Closed -$1.04M – 1284
2025
Q3 		$1.04M Buy
+26,241
New +$1M 0.08% 301

Other funds holding APGE

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Prelude Capital Management's APGE Position: Q1 2026 in Review

Prelude Capital Management opened a new position in Apogee Therapeutics (APGE) in Q1 2026: 6,000 shares worth $505K. The stake represents 0.04% of the portfolio and ranks #505 among its holdings. This is a return to the name: Prelude Capital Management previously reported a position in APGE as recently as Q3 2025.

Prelude Capital Management first reported a position in APGE in Q3 2025 and has held it in 2 quarters since. The position peaked at $1.04M in Q3 2025. 224 funds tracked by Wall St. Rank hold APGE as of Q1 2026.

  • Prelude Capital Management held 6,000 shares of Apogee Therapeutics worth $505K as of Q1 2026.
  • Apogee Therapeutics was a new Prelude Capital Management position in Q1 2026.
  • Apogee Therapeutics made up 0.04% of Prelude Capital Management's portfolio in Q1 2026, its #505 holding.
  • Prelude Capital Management first reported a position in Apogee Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • Prelude Capital Management's Apogee Therapeutics position peaked at $1.04M in Q3 2025.
  • 224 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.